PE20051162A1 - IMPURITIES REDUCTION METHOD IN SCCITALOPRAM - Google Patents

IMPURITIES REDUCTION METHOD IN SCCITALOPRAM

Info

Publication number
PE20051162A1
PE20051162A1 PE2005000241A PE2005000241A PE20051162A1 PE 20051162 A1 PE20051162 A1 PE 20051162A1 PE 2005000241 A PE2005000241 A PE 2005000241A PE 2005000241 A PE2005000241 A PE 2005000241A PE 20051162 A1 PE20051162 A1 PE 20051162A1
Authority
PE
Peru
Prior art keywords
particle size
escitalopram
mean
refers
sccitalopram
Prior art date
Application number
PE2005000241A
Other languages
Spanish (es)
Inventor
Kim Bojstrup Jensen
Ken Liljegren
Troels Volsgaard Christensen
Rikke Eva Humble
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PE20051162A1 publication Critical patent/PE20051162A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A PARTICULAS CRISTALINAS DE OXALATO DE ESCITALOPRAM, EL CUAL LA RELACION ENTRE LA MEDIA DEL TAMANO DE PARTICULA Y EL TAMANO DE LA PARTICULA EN EL 95% DEL QUINTILO ES INFERIOR A 0.42 Y LA MEDIA ES DE POR LO MENOS 20um. LA DISTRIBUCION DEL TAMANO DE PARTICULA ES BIMODAL O POLIMODAL. DICHA PARTICULA SE OBTIENE DE: A) TRATAR UNA SOLUCION DE ESCITALOPRAM CON UNO O MAS HIDROXILOS QUE CONTIENEN IMPUREZAS CON UN DEPURADOR DE HIDROXILO; B) SEPARAR EL ESCITALOPRAM DE LOS PRODUCTOS RESULTANTES; C) TRANFERIR EN SU SAL DE OXALATO Y LLEVAR A UN SISTEMA DE SOLVENTES APROPIADOS PARA LA CRISTALIZACION; D) ENFRIAR GRADUALMENTE EN UN PERFIL DE ENFRIAMIENTO CONTROLADO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, SIENDO UTILES EN LA MANUFACTURA DE TABLETAS DIRECTAMENTE COMPRIMIDASREFERS TO CRYSTALLINE PARTICLES OF ESCITALOPRAM OXALATE, WHICH THE RELATIONSHIP BETWEEN THE MEAN OF THE PARTICLE SIZE AND THE PARTICLE SIZE IN 95% OF THE QUINTILE IS LESS THAN 0.42 AND THE MEAN IS AT LEAST 20um. THE DISTRIBUTION OF THE PARTICLE SIZE IS BIMODAL OR POLYMODAL. SUCH PARTICULAR IS OBTAINED FROM: A) TREATING A SOLUTION OF ESCITALOPRAM WITH ONE OR MORE HYDROXYLS CONTAINING IMPURITIES WITH A HYDROXYL CLEANER; B) SEPARATE THE ESCITALOPRAM FROM THE RESULTING PRODUCTS; C) TRANSFER IN ITS OXALATE SALT AND TAKE TO A SYSTEM OF APPROPRIATE SOLVENTS FOR THE CRYSTALIZATION; D) COOLING GRADUALLY IN A CONTROLLED COOLING PROFILE. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION, BEING USEFUL IN THE MANUFACTURE OF DIRECTLY COMPRESSED TABLETS

PE2005000241A 2004-03-05 2005-03-02 IMPURITIES REDUCTION METHOD IN SCCITALOPRAM PE20051162A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200400382 2004-03-05

Publications (1)

Publication Number Publication Date
PE20051162A1 true PE20051162A1 (en) 2006-01-16

Family

ID=36607154

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000241A PE20051162A1 (en) 2004-03-05 2005-03-02 IMPURITIES REDUCTION METHOD IN SCCITALOPRAM

Country Status (9)

Country Link
KR (1) KR20060126587A (en)
CN (3) CN101492435A (en)
AR (1) AR047749A1 (en)
IL (1) IL177504A0 (en)
MY (1) MY142756A (en)
PE (1) PE20051162A1 (en)
SG (1) SG159504A1 (en)
TW (1) TW200605916A (en)
ZA (1) ZA200607382B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114763343A (en) * 2021-01-14 2022-07-19 浙江华海药业股份有限公司 Method for purifying citalopram or S-citalopram
CN113663356B (en) * 2021-08-23 2022-09-23 广西埃索凯新材料科技有限公司 Crystallization impurity removal monitoring system applied to manganese sulfate production

Also Published As

Publication number Publication date
TW200605916A (en) 2006-02-16
CN1925844A (en) 2007-03-07
ZA200607382B (en) 2008-05-28
CN101492435A (en) 2009-07-29
IL177504A0 (en) 2006-12-10
AR047749A1 (en) 2006-02-15
MY142756A (en) 2010-12-31
KR20060126587A (en) 2006-12-07
CN101492436A (en) 2009-07-29
SG159504A1 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
ES2610988T3 (en) Tablet containing cannabidiol, method for its production and use of such tablet in the oral treatment of psychotic or anxiety disorders
Zhao et al. Non-interfacial growth of Cu3Sn in Cu/Sn/Cu joints during ultrasonic-assisted transient liquid phase soldering process
AR044140A1 (en) SOLIDIFICATION PROCESS WITH ANTISOLVENT, CRYSTAL PARTICLES OBTAINED BY SUCH PROCESS AND PHARMACEUTICAL DOSAGE FORM THAT UNDERSTANDS
CL2013003554A1 (en) Solid pharmaceutical dosage form in the form of a dispersion or solid solution comprising ritonavir, between 50-80% by weight of at least one water soluble polymer with a tg of at least 50 ° C, based on the total weight of the dosage form , and a surfactant (divisional of the sun. 1844-2009 and this divisional of the sun. 393-2006).
CO5670354A2 (en) PROCESS FOR THE PREPARATION OF DESIRED AVERAGE PARTICULAR STERILE ARIPIPRAZOL
NO20091108L (en) Method of Removing Iodide Compound from Organic Acid
AR062980A1 (en) PHARMACEUTICAL COMPOSITIONS OF PIRIMIDIL-AMINO-BENZAMIDA COMPOUNDS
EP2039674A3 (en) Improved process for selective reduction of propionic acid from (meth)acrylic acid product streams
PE20051162A1 (en) IMPURITIES REDUCTION METHOD IN SCCITALOPRAM
WO2010113179A3 (en) Process for purifying eslicarbazepine acetate
PE20061007A1 (en) PROCESS TO PREPARE LACTOSE USING PRE-CLASSIFICATION TECHNIQUES AND PHARMACEUTICAL FORMULATIONS FORMED FROM IT
CN101371996A (en) Combined magnetic force separating mechanism for removing iron dust in plastic
BRPI0104932B8 (en) method for discharging a reduced product from a mobile furnace furnace and unloading device
JP2004284680A (en) Tablet cassette arrangement board of automatic tablet distribution and packaging device
ES2577150T3 (en) Pharmaceutical preparation containing selenite or compounds containing selenite for the treatment of dysplasia or cervical carcinomas
WO2008113792A3 (en) Production of thorium 228 starting from a natural thorium salt
JP2010508299A5 (en)
JP2008504228A5 (en)
ES2183522T3 (en) CRYSTALIZATION OF LACTITOL, PRODUCT OF LACTITOL CRISTALINO AND USE OF THE SAME.
CN204051742U (en) The husk rice of twill salient point six prismatic is sieved
FR2847487B1 (en) PROCESS FOR PRODUCING PARTICLES
FR2905374B1 (en) PROCESS FOR THE PREPARATION OF HIGH PURITY HYDROQUINONE
CN103819442A (en) Synthesis technology of active natural product dihydromyricetin
CN202570727U (en) Air purification device for film production workshop
CN201366250Y (en) Dual ring liquid basin

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed